Fig. 4From: Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancerProstate cancer treatment specific QOL scores following treatment. EPIC-26 scores in the urinary (a), sexual (b), bowel (c), and hormonal (d) domains at baseline and 3, 12, 24, and 36 months post-treatment. The number of responses obtained at each time point is indicatedBack to article page